Novavax to Participate in Upcoming September Conferences

Core Insights - Novavax, Inc. will participate in two upcoming investor conferences in September 2024, showcasing its advancements in protein-based vaccines and its novel Matrix-M™ adjuvant [1][2]. Group 1: Upcoming Conferences - Novavax will engage in the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, with a fireside chat scheduled from 3:30 to 4:00 p.m. ET [2]. - The company will also present at the Baird 2024 Global Healthcare Conference on September 10, 2024, from 3:10 to 3:40 p.m. ET [2]. - Both events will feature key executives, including Jim Kelly, CFO, and Robert Walker, MD, CMO, highlighting the company's strategic direction and developments [2]. Group 2: Company Overview - Novavax is focused on discovering, developing, and commercializing innovative vaccines to combat serious infectious diseases, utilizing a recombinant protein approach and nanoparticle technology [3]. - The company's portfolio includes a COVID-19 vaccine and candidates for COVID-19-Influenza Combination and standalone influenza vaccines [3]. - Novavax's patented Matrix-M adjuvant is also part of the malaria vaccine developed by the University of Oxford and Serum Institute of India [3].